Announcements

    Drinks

      Scope has updated its analytical report on Uniper SE
      TUESDAY, 02/07/2024 - Scope Ratings GmbH
      Download PDF

      Scope has updated its analytical report on Uniper SE

      Following the recent affirmation of the BBB-/Stable issuer rating, Scope has updated its analytical report on Uniper SE.

      This monitoring note does not constitute a credit rating action, nor does it indicate the likelihood that Scope will conduct a credit rating action in the short term. On 26 June 2024, Scope affirmed the BBB-/Stable issuer rating on Uniper SE. Scope also affirmed the senior unsecured debt rating at BBB- and the short-term debt rating at S-2.

      The latest information on the credit ratings in this monitoring note along with the associated rating history can be found on www.scoperatings.com.

      Click here to access the full report.

      Related news

      Show all
      Scope affirms BBB-/Stable issuer rating of Germany’s investment holding Haniel

      17/4/2025 Rating announcement

      Scope affirms BBB-/Stable issuer rating of Germany’s ...

      Trade tensions, OPEC+ production hikes weigh down on oil & gas credit outlook

      17/4/2025 Research

      Trade tensions, OPEC+ production hikes weigh down on oil & ...

      Scope affirms B+ issuer rating on consumer goods company Naturtex and revises Outlook to Stable

      15/4/2025 Rating announcement

      Scope affirms B+ issuer rating on consumer goods company ...

      Scope proposes an update to its Chemicals Rating Methodology and invites comments

      14/4/2025 Research

      Scope proposes an update to its Chemicals Rating Methodology ...

      US tariff increases to have uneven direct cashflow, credit impact on European corporates

      11/4/2025 Research

      US tariff increases to have uneven direct cashflow, credit ...

      Scope proposes an update to its Pharmaceutical Companies’ Rating Methodology and invites comments

      4/4/2025 Research

      Scope proposes an update to its Pharmaceutical Companies’ ...